Jean-SÃ©bastien Delisle

List of Publications by Year
in descending order

45 papers	1,058 citations	567281 15 h-index	434195 31 g-index
48 all docs	48 docs citations	48 times ranked	1910 citing authors

#	Article	IF	Citations
1	Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Reviews, 2023, 57, 100991.	5.7	5
2	Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. Bone Marrow Transplantation, 2022, 57, 252-260.	2.4	6
3	Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma. Blood Cancer Journal, 2022, 12, 3.	6.2	5
4	Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective. Transplantation and Cellular Therapy, 2022, 28, 145-151.	1.2	4
5	UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe Infections. Transplantation and Cellular Therapy, 2021, 27, 76.e1-76.e9.	1.2	11
6	T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. Cancers, 2021, 13, 598.	3.7	19
7	Myeloidâ€resident neuropilinâ€1 promotes choroidal neovascularization while mitigating inflammation. EMBO Molecular Medicine, 2021, 13, e11754.	6.9	9
8	Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity, 2021, 54, 737-752.e10.	14.3	58
9	p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells. Frontiers in Immunology, 2021, 12, 698565.	4.8	16
10	Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. Biology of Blood and Marrow Transplantation, 2020, 26, 157-161.	2.0	13
11	Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1â€“2 safety and feasibility study. Lancet Haematology,the, 2020, 7, e134-e145.	4.6	138
12	Single UM171â€expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors. European Journal of Haematology, 2020, 105, 808-811.	2.2	3
13	T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies. Frontiers in Immunology, 2020, 11, 276.	4.8	38
14	Newly diagnosed multiple myeloma patients treated with tandem autoâ€allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only. Clinical Transplantation, 2020, 34, e14099.	1.6	4
15	UM171-Expanded Cord Blood Transplants Support Robust T-Cell Reconstitution with Low Rates of Severe Infections. Blood, 2020, 136, 36-37.	1.4	2
16	TGFÎ² Programs Central Memory Differentiation inEx Vivoâ€“Stimulated Human T Cells. Cancer Immunology Research, 2019, 7, 1426-1439.	3.4	19
17	On-chip refractive index cytometry for whole-cell deformability discrimination. Lab on A Chip, 2019, 19, 464-474.	6.0	13
18	Leukoreduction system chambers are a reliable cellular source for the manufacturing of Tâ€cell therapeutics. Transfusion, 2019, 59, 1300-1311.	1.6	9

#	Article	IF	Citations
19	Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. Leukemia Research, 2019, 79, 75-80.	0.8	8
20	Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity. Biology of Blood and Marrow Transplantation, 2019, 25, 19-25.	2.0	16
21	High-throughput refractive index-based microphotonic sensor for enhanced cellular discrimination. Sensors and Actuators B: Chemical, 2018, 266, 255-262.	7.8	8
22	TGF-Î² in T Cell Biology: Implications for Cancer Immunotherapy. Cancers, 2018, 10, 194.	3.7	132
23	Single UM171 Expanded Cord Blood Permits Transplantation of Better HLA Matched Cords with Excellent Gvhd Relapse Free Survival. Blood, 2018, 132, 4658-4658.	1.4	3
24	Clinical-Scale Rapid Autologous BK Virus-Specific T Cell Line Generation From Kidney Transplant Recipients With Active Viremia for Adoptive Immunotherapy. Transplantation, 2017, 101, 2713-2721.	1.0	19
25	Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers. Current Drug Targets, 2017, 18, 281-295.	2.1	12
26	BK Polyomavirus and the Transplanted Kidney. Transplantation, 2016, 100, 2276-2287.	1.0	70
27	Favorable Long-Term Survival of Newly Diagnosed Multiple Myeloma Patients Using a Frontline Outpatient Tandem Approach. Biology of Blood and Marrow Transplantation, 2016, 22, S353-S354.	2.0	0
28	Bortezomib Consolidation after Allogeneic Nonmyeloablative Transplantation to Improve Outcome in Poor Prognosis Multiple Myeloma Patients: A Preliminary Safety Report. Biology of Blood and Marrow Transplantation, 2016, 22, S352-S353.	2.0	0
29	The Importance of Single-Mode Behavior in Silicon-On-Insulator Rib Waveguides With Very Large Cross Section for Resonant Sensing Applications. IEEE Journal of Selected Topics in Quantum Electronics, 2016, 22, 241-248.	2.9	10
30	VEGF Requires the Receptor NRP-1 To Inhibit Lipopolysaccharide-Dependent Dendritic Cell Maturation. Journal of Immunology, 2016, 197, 3927-3935.	0.8	43
31	Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture. Journal of Translational Medicine, 2015, 13, 123.	4.4	24
32	Early exposure to interleukin-21 limits rapidly generated antiâ€“Epstein-Barr virus T-cell line differentiation. Cytotherapy, 2015, 17, 496-508.	0.7	16
33	Phase I Study of Non-Engrafting Allogeneic, Mismatched, Unmanipulated Peripheral Blood Mononuclear Cell Infusions to Treat Poor-Prognosis Acute Myeloid Leukemia. Blood, 2015, 126, 2562-2562.	1.4	1
34	Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Reviews, 2014, 28, 249-261.	5.7	16
35	TGF-Î² signaling favors central memory differentiation of ex-vivo stimulated human T cells. Experimental Hematology, 2014, 42, S30.	0.4	0
36	Neuropilin-1 mediates myeloid cell chemoattraction and influences retinal neuroimmune crosstalk. Journal of Clinical Investigation, 2014, 124, 4807-4822.	8.2	74

#	Article	IF	Citations
37	Prompt Treatment of Respiratory Syncytial Virus with Inhaled Ribavirin and IVIG in High Risk Allogeneic Stem Cell Transplant Recipients Significantly Diminishes Mortality. Biology of Blood and Marrow Transplantation, 2013, 19, S258-S259.	2.0	0
38	Pneumatosis Coli Associated to Severe Intestinal Graft Versus Host Disease Following Hematopoietic Cell Transplantation: Risk Factors and Dismal Outcome. Biology of Blood and Marrow Transplantation, 2013, 19, S333.	2.0	1
39	Immunoregulatory CD4-CD8- T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer. Frontiers in Immunology, 2013, 4, 6.	4.8	33
40	Roles of Transforming Growth Factor-Î² in Graft-versus-Host and Graft-versus-Tumor Effects. Biology of Blood and Marrow Transplantation, 2012, 18, 1329-1340.	2.0	15
41	SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage. Blood, 2011, 117, 1734-1744.	1.4	42
42	T Cell Activation Leads to Protein Kinase CÎ¸-Dependent Inhibition of TGF-Î² Signaling. Journal of Immunology, 2010, 185, 1568-1576.	0.8	16
43	Graft-versus-host disease causes failure of donor hematopoiesis and lymphopoiesis in interferon-Î³ receptor-deficient hosts. Blood, 2008, 112, 2111-2119.	1.4	42
44	T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nature Medicine, 2005, 11, 1222-1229.	30.7	71
45	Coexpression of rat glutathione S-transferase A3 and human cytidine deaminase by a bicistronic retroviral vector confers in vitro resistance to nitrogen mustards and cytosine arabinoside in murine fibroblasts. Cancer Gene Therapy, 2000, 7, 757-765.	4.6	14